Internal Medicine, Gastroenterology · Brick, NJ
NPI
1962507251
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
525 Jack Martin Blvd, Suite 300
Brick, NJ, 08724
Phone (732) 840-0067
Groups this clinician bills Medicare through
Medicare paid, 2024
$207K
2,238 services
Medicare patients, 2024
1,002
Average age 75
Drug cost, 2024
$753K
2,933 prescriptions
Company payments, 2025
$330
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Assif Rozovsky was code 99214 (office e&m - established), 666 times for 407 patients. In total Assif Rozovsky billed 2,238 services in 37 codes, and Medicare paid $207K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 666 | 407 | $99.26 | $66K |
| 99232 Hospital E&M - Subsequent | Facility | 426 | 280 | $64.25 | $27K |
| 43239 Upper GI Endoscopy | Facility | 187 | 186 | $98.77 | $18K |
| 99222 Hospital E&M - Initial | Facility | 140 | 136 | $105.76 | $15K |
| 45380 Lower GI Endoscopy - Other | Facility | 129 | 129 | $134.17 | $17K |
| 99213 Office E&M - Established | Office | 118 | 112 | $72.77 | $8,587 |
| 99204 Office E&M - New | Office | 111 | 111 | $124.17 | $14K |
| 99231 Hospital E&M - Subsequent | Facility | 88 | 61 | $40.94 | $3,603 |
| 43450 Digestive/Gastrointestinal | Facility | 79 | 79 | $33.08 | $2,613 |
| 45378 Lower GI Endoscopy - Other | Facility | 48 | 47 | $134.89 | $6,475 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 28 | 28 | $156.88 | $4,393 |
| 45385 Colonoscopy - Lesion Removal | Facility | 28 | 28 | $218.36 | $6,114 |
| 99233 Hospital E&M - Subsequent | Facility | 19 | 16 | $82.01 | $1,558 |
| 43255 Upper GI Endoscopy | Facility | 15 | 11 | $158.45 | $2,377 |
| 99203 Office E&M - New | Office | 14 | 14 | $86.47 | $1,211 |
By year: 2022 $147K for 1,486 services; 2023 $169K for 1,858 services; 2024 $207K for 2,238 services.
Medicare prescription drug claims, 2024
In 2024, the drug Assif Rozovsky prescribed most often to Medicare patients was Rabeprazole Sodium, with 428 prescriptions and refills. In total Assif Rozovsky wrote 2,933 Medicare prescriptions that cost $753K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rabeprazole Sodium Generic | 428 | 899 | 135 | $14K |
| Pantoprazole Sodium Generic | 367 | 809 | 91 | $4,106 |
| Famotidine Generic | 362 | 758 | 112 | $3,880 |
| Omeprazole Generic | 330 | 737 | 88 | $3,665 |
| Dicyclomine Hcl Generic | 250 | 402 | 77 | $4,594 |
| Sucralfate Generic | 189 | 302 | 62 | $8,041 |
| Methscopolamine Bromide Generic | 86 | 154 | 25 | $5,305 |
| Glycopyrrolate Generic | 83 | 181 | 39 | $1,987 |
| Dexlansoprazole Dr Dexlansoprazole | 82 | 182 | 29 | $31K |
| Alprazolam Generic | 72 | 73 | 19 | $255 |
| Cholestyramine Cholestyramine (With Sugar) | 48 | 57 | Under 11 | $2,640 |
| Ondansetron Odt Ondansetron | 41 | 45 | 27 | $1,309 |
| Esomeprazole Magnesium Generic | 34 | 94 | 12 | $1,899 |
| Mesalamine Generic | 32 | 57 | 12 | $6,360 |
| Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate | 31 | 77 | Under 11 | $6,137 |
Brand drugs: - claims; generic drugs: 2,673 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Assif Rozovsky $330 ($330 in general payments such as food, travel and fees) from 6 companies. The largest payer was Janssen Biotech, Inc. with $139.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.